Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Groen

Showing results (411-420 of 456) with videos related to

Pageof 46
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, et al.
Haematologica|August 11, 2011
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiationRichard W J Groen, Martin F M de Rooij, Kinga A Kocemba, et al.
The British Journal of Surgery|June 22, 2021
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancerM E M van der Noordaa, F H van Duijnhoven, F N E Cuijpers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of ApoptosisLisa C Holthof, Jort J van der Schans, Afroditi Katsarou, et al.
Journal of Clinical Microbiology|March 4, 2000
Serological and virological characterization of clinically diagnosed cases of measles in suburban KhartoumH S el Mubarak, M W Van De Bildt, O A Mustafa, et al.
Expert Review of Clinical Immunology|February 22, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experienceKristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, et al.
Breast (Edinburgh, Scotland)|February 15, 2025
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocolAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2013
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistanceSanne J de Haart, Niels W C J van de Donk, Monique C Minnema, et al.
Biomolecules|December 30, 2025
Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone DiseaseJiaxian Wang, Thomas Baardemans, Ricardo de Matos Simoes, et al.
Breast Cancer Research and Treatment|March 3, 2022
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocolAriane A van Loevezijn, Marieke E M van der Noordaa, Marcel P M Stokkel, et al.
Pageof 46

Showing results (411-420 of 456) with videos related to

Sort By:
Pageof 46
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, et al.
Haematologica|August 11, 2011
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiationRichard W J Groen, Martin F M de Rooij, Kinga A Kocemba, et al.
The British Journal of Surgery|June 22, 2021
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancerM E M van der Noordaa, F H van Duijnhoven, F N E Cuijpers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of ApoptosisLisa C Holthof, Jort J van der Schans, Afroditi Katsarou, et al.
Journal of Clinical Microbiology|March 4, 2000
Serological and virological characterization of clinically diagnosed cases of measles in suburban KhartoumH S el Mubarak, M W Van De Bildt, O A Mustafa, et al.
Expert Review of Clinical Immunology|February 22, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experienceKristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, et al.
Breast (Edinburgh, Scotland)|February 15, 2025
Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocolAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2013
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistanceSanne J de Haart, Niels W C J van de Donk, Monique C Minnema, et al.
Biomolecules|December 30, 2025
Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone DiseaseJiaxian Wang, Thomas Baardemans, Ricardo de Matos Simoes, et al.
Breast Cancer Research and Treatment|March 3, 2022
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocolAriane A van Loevezijn, Marieke E M van der Noordaa, Marcel P M Stokkel, et al.
Pageof 46